FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560219091> ?p ?o ?g. }

• W2560219091 endingPage "588" @default.
• W2560219091 startingPage "580" @default.
• W2560219091 abstract "Patients with sickle cell anaemia (SCA) have vaso-occlusive crises resulting from occlusive hypoxic-ischaemic injury. Prasugrel inhibits platelet activation and aggregation involved in SCA pathophysiology. Determining Effects of Platelet Inhibition on Vaso-Occlusive Events (DOVE) was a phase 3, double-blind, randomised, placebo-controlled trial assessing prasugrel efficacy. DOVE sought to bring patients' P2Y12 reaction unit (PRU) value within a targeted range via prasugrel dose adjustments using encrypted VerifyNow P2Y12® (VN-P2Y12) point-of-care testing and an interactive voice-response system (IVRS). After PRU determination, randomised patients received 0.08 mg/kg/day prasugrel or placebo. Encrypted PRUs and IVRS provided double-blind dose adjustments to achieve a defined PRU target range of 136-231; placebo patients had mock titrations. Of 341 randomised patients, 166 placebo and 160 prasugrel patients reached the fully titrated dose (FTD). Most prasugrel patients (n=104, 65 %) remained on the initial 0.08 mg/kg dose; doses escalations occurred in 23 % of patients (n=36). Mean PRUs for the pharmacodynamic population at baseline were similar in the prasugrel (273 ± 44.9) and placebo groups (273 ± 51.7), with significant reductions in PRU (p<0.001) for prasugrel patients at the FTD and at 9 months. Concomitant use of hydroxyurea did not affect platelet reactivity at any time. The majority of prasugrel patients (n=135, 84.4 %) at the FTD were within the target range of 136-231 PRUs. Mean VN-P2Y12 percentage inhibition at baseline was similar in the prasugrel (2.8 ± 5.4 %) and placebo groups (2.0 ± 4.7 %); prasugrel patients had significant increases in inhibition (p<0.001) at FTD and at 9 months. Patients with higher PRU values at baseline required higher prasugrel doses to bring PRU within the prespecified range. DOVE is the first study to successfully employ double-blind, real-time, encrypted, point-of-care platelet testing and IVRS to dose-adjust antiplatelet therapy to a targeted range of platelet inhibition." @default.
• W2560219091 created "2016-12-16" @default.
• W2560219091 creator A5001718098 @default.
• W2560219091 creator A5001812366 @default.
• W2560219091 creator A5008442666 @default.
• W2560219091 creator A5009241415 @default.
• W2560219091 creator A5009513049 @default.
• W2560219091 creator A5044957715 @default.
• W2560219091 creator A5050462394 @default.
• W2560219091 creator A5062092404 @default.
• W2560219091 creator A5064328568 @default.
• W2560219091 creator A5077501925 @default.
• W2560219091 creator A5085093775 @default.
• W2560219091 creator A5085474359 @default.
• W2560219091 creator A5086949065 @default.
• W2560219091 date "2017-01-01" @default.
• W2560219091 modified "2023-09-22" @default.
• W2560219091 title "Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia" @default.
• W2560219091 cites W1538485586 @default.
• W2560219091 cites W1893676737 @default.
• W2560219091 cites W1990018236 @default.
• W2560219091 cites W2003593234 @default.
• W2560219091 cites W2015825692 @default.
• W2560219091 cites W2052036318 @default.
• W2560219091 cites W2064255415 @default.
• W2560219091 cites W2104595603 @default.
• W2560219091 cites W2111109999 @default.
• W2560219091 cites W2118791457 @default.
• W2560219091 cites W2139585567 @default.
• W2560219091 cites W2140730992 @default.
• W2560219091 cites W2145171892 @default.
• W2560219091 cites W2148363808 @default.
• W2560219091 cites W2295195689 @default.
• W2560219091 cites W2322613240 @default.
• W2560219091 cites W2411846615 @default.
• W2560219091 cites W2913013323 @default.
• W2560219091 doi "https://doi.org/10.1160/th16-09-0731" @default.
• W2560219091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27929203" @default.
• W2560219091 hasPublicationYear "2017" @default.
• W2560219091 type Work @default.
• W2560219091 sameAs 2560219091 @default.
• W2560219091 citedByCount "14" @default.
• W2560219091 countsByYear W25602190912017 @default.
• W2560219091 countsByYear W25602190912018 @default.
• W2560219091 countsByYear W25602190912019 @default.
• W2560219091 countsByYear W25602190912020 @default.
• W2560219091 countsByYear W25602190912021 @default.
• W2560219091 countsByYear W25602190912022 @default.
• W2560219091 crossrefType "journal-article" @default.
• W2560219091 hasAuthorship W2560219091A5001718098 @default.
• W2560219091 hasAuthorship W2560219091A5001812366 @default.
• W2560219091 hasAuthorship W2560219091A5008442666 @default.
• W2560219091 hasAuthorship W2560219091A5009241415 @default.
• W2560219091 hasAuthorship W2560219091A5009513049 @default.
• W2560219091 hasAuthorship W2560219091A5044957715 @default.
• W2560219091 hasAuthorship W2560219091A5050462394 @default.
• W2560219091 hasAuthorship W2560219091A5062092404 @default.
• W2560219091 hasAuthorship W2560219091A5064328568 @default.
• W2560219091 hasAuthorship W2560219091A5077501925 @default.
• W2560219091 hasAuthorship W2560219091A5085093775 @default.
• W2560219091 hasAuthorship W2560219091A5085474359 @default.
• W2560219091 hasAuthorship W2560219091A5086949065 @default.
• W2560219091 hasConcept C126322002 @default.
• W2560219091 hasConcept C142724271 @default.
• W2560219091 hasConcept C204787440 @default.
• W2560219091 hasConcept C27081682 @default.
• W2560219091 hasConcept C2777028646 @default.
• W2560219091 hasConcept C2777849778 @default.
• W2560219091 hasConcept C2779837110 @default.
• W2560219091 hasConcept C2908647359 @default.
• W2560219091 hasConcept C42219234 @default.
• W2560219091 hasConcept C49059817 @default.
• W2560219091 hasConcept C500558357 @default.
• W2560219091 hasConcept C71924100 @default.
• W2560219091 hasConcept C90924648 @default.
• W2560219091 hasConcept C99454951 @default.
• W2560219091 hasConceptScore W2560219091C126322002 @default.
• W2560219091 hasConceptScore W2560219091C142724271 @default.
• W2560219091 hasConceptScore W2560219091C204787440 @default.
• W2560219091 hasConceptScore W2560219091C27081682 @default.
• W2560219091 hasConceptScore W2560219091C2777028646 @default.
• W2560219091 hasConceptScore W2560219091C2777849778 @default.
• W2560219091 hasConceptScore W2560219091C2779837110 @default.
• W2560219091 hasConceptScore W2560219091C2908647359 @default.
• W2560219091 hasConceptScore W2560219091C42219234 @default.
• W2560219091 hasConceptScore W2560219091C49059817 @default.
• W2560219091 hasConceptScore W2560219091C500558357 @default.
• W2560219091 hasConceptScore W2560219091C71924100 @default.
• W2560219091 hasConceptScore W2560219091C90924648 @default.
• W2560219091 hasConceptScore W2560219091C99454951 @default.
• W2560219091 hasIssue "03" @default.
• W2560219091 hasLocation W25602190911 @default.
• W2560219091 hasLocation W25602190912 @default.
• W2560219091 hasOpenAccess W2560219091 @default.
• W2560219091 hasPrimaryLocation W25602190911 @default.
• W2560219091 hasRelatedWork W1893676737 @default.
• W2560219091 hasRelatedWork W2031499028 @default.
• W2560219091 hasRelatedWork W2035827787 @default.

• next